Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2003 1
2004 5
2005 3
2006 5
2007 5
2008 8
2009 4
2010 7
2011 25
2012 19
2013 18
2014 22
2015 25
2016 14
2017 12
2018 20
2019 18
2020 15
2021 16
2022 19
2023 23
2024 13

Text availability

Article attribute

Article type

Publication date

Search Results

268 results

Results by year

Filters applied: . Clear all
Page 1
Interim safety and immunogenicity of COVID-19 omicron BA.1 variant-containing vaccine in children in the USA: an open-label non-randomised phase 3 trial.
Dixit A, Bennett R, Ali K, Griffin C, Clifford RA, Turner M, Poston R, Hautzinger K, Yeakey A, Girard B, Zhou W, Deng W, Zhou H, Schnyder Ghamloush S, Kuter BJ, Slobod K, Miller JM, Priddy F, Das R; ROVER Study Investigators. Dixit A, et al. Among authors: miller jm. Lancet Infect Dis. 2024 Mar 19:S1473-3099(24)00101-4. doi: 10.1016/S1473-3099(24)00101-4. Online ahead of print. Lancet Infect Dis. 2024. PMID: 38518789
No immunological interference or concerns about safety when seasonal quadrivalent influenza vaccine is co-administered with a COVID-19 mRNA-1273 booster vaccine in adults: A randomized trial.
Naficy A, Kuxhausen A, Seifert H, Hastie A, Leav B, Miller J, Anteyi K, Mwakingwe-Omari A. Naficy A, et al. Among authors: miller j. Hum Vaccin Immunother. 2024 Dec 31;20(1):2327736. doi: 10.1080/21645515.2024.2327736. Epub 2024 Mar 21. Hum Vaccin Immunother. 2024. PMID: 38513689 Free PMC article. Clinical Trial.
Interim report of the reactogenicity and immunogenicity of SARS-CoV-2 XBB-containing vaccines.
Chalkias S, McGhee N, Whatley JL, Essink B, Brosz A, Tomassini JE, Girard B, Edwards DK, Wu K, Nasir A, Lee D, Avena LE, Feng J, Deng W, Montefiori DC, Baden LR, Miller JM, Das R. Chalkias S, et al. Among authors: miller jm. J Infect Dis. 2024 Feb 13:jiae067. doi: 10.1093/infdis/jiae067. Online ahead of print. J Infect Dis. 2024. PMID: 38349280
268 results